viewVectura Group PLC

Vectura investors breathe sigh of relief as inhaler sales pick up in first half

Vectura's adjusted underlying earnings (EBITDA) rose more than 50% to £24.6mln on higher revenue of £79.9mln

woman with inhaler
Vectura's flutiform inhaler comfortably outperformed the market in the first half

Vectura Group PLC (LON:VEC) shares nudged higher on Tuesday after the inhaler maker posted a solid set of interim results and reiterated its full-year guidance.

Sales of its flutiform asthma inhaler fell off towards the end of 2017 as a result of de-stocking, but they picked up again in the opening six months of 2018, despite the market itself actually declining.

READ: Vectura expects revenue rise despite Advair blow

That was reflective of the group’s inhaled portfolio as a whole, with revenue in the division climbing 7.1%, more than offsetting a 17.4% slide in revenues from its smaller non-inhaled business.

In total, revenue for the six months through to the end of June rose 1.4% to £79.9mln (H1 17: £78.8mln).

Adjusted underlying earnings (EBITDA) rose more than 50% to £24.6mln (H1 17: £16.2mln) as Vectura benefitted from better procurement and stronger operating margins.

The interim operating loss narrowed substantially to £30.2mln (H1 17: £41.3mln) driven by lower amortisation and R&D costs.

Momentum is back

“Vectura is regaining momentum after a challenging 2017,” said chief executive James Ward-Lilley.

“Inhaled in-market growth is continuing with flutiform stock levels normalising resulting in total inhaled Vectura revenues increasing 7.1% vs H1 2017.

“Our refocussed pipeline is making progress with Phase II VR647 results a key highlight in H1 2018. We have identified and are progressing a series of new pipeline projects, and we look forward to the read-out of the VR475 Phase III adult asthma study later this year.”

Ward-Lilley maintained the firm’s full-year guidance, with analysts forecasting 2018 sales of around £159mln and EBITDA of £31.6mln.

79% of EBITDA secured already

“Vectura’s £24.6mln H1 EBITDA represents 79% of the consensus £31mln FY2018 forecast,” read a Peel Hunt note to clients.

“Positive momentum has returned to the inhaled portfolio, which should be taken positively. However, Vectura has maintained its FY2018 outlook, and revenue and R&D expense phasing likely limits the scope for material forecast upgrades.

“Nevertheless, with the stock down c37% year-to-date, we believe these optically solid interim results are likely to provide a fillip to the shares today.”

Shares rose 1.5% on Tuesday to 75.1p.

Quick facts: Vectura Group PLC

Price: 97.7 GBX

Market: AIM
Market Cap: £588.37 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Electric vehicle sales to accelerate following coronavirus pandemic

Roskill analyst Jose Lazuen tells Proactive London's Andrew Scott severe falls were expected in EV sales but that European and Chinese policies coupled with consumer preferences have shown them to remain strong. He adds that policy is going to favour and push EV sales in certain jurisdictions...

1 day, 11 hours ago

2 min read